| SGLT2i在合并糖尿病动脉粥样硬化性心血管疾病中的作用研究进展 |
| |
| 引用本文： | 王继航,沈明志,焦阳,付振虹. SGLT2i在合并糖尿病动脉粥样硬化性心血管疾病中的作用研究进展[J]. 中华老年多器官疾病杂志, 2021, 20(4): 300-304 |
| |
| 作者姓名： | 王继航 沈明志 焦阳 付振虹 |
| |
| 作者单位： | 解放军医学院,北京 100853;解放军总医院第一医学中心心血管内科,北京 100853;解放军总医院海南医院心血管内科,海南 三亚 572013,解放军总医院海南医院心血管内科,海南 三亚 572013,解放军医学院,北京 100853;解放军总医院第一医学中心心血管内科,北京 100853,解放军总医院第一医学中心心血管内科,北京 100853;解放军总医院国家老年疾病临床医学研究中心,北京 100853 |
| |
| 基金项目： | 国家自然科学基金(81500269)；解放军总医院国家老年疾病临床医学研究中心开放课题(NCRCG-PLAGH-2019002) |
| |
| 摘 要： | 糖尿病是一种全球流行病,血糖控制不佳是导致心血管疾病患者死亡的主要原因之一.作为新型降糖药,钠-葡萄糖共转运体2抑制剂(SGLT2i)由于其在临床和基础研究中表现出卓越的心血管系统保护作用而倍受关注.前期针对SGLT2i的大型随机对照试验(EMPA-RED研究、CANVAS研究、DELCARE TIMI-58研究)均证...
|
| 关 键 词： | 心血管疾病 SGLT2抑制剂 糖尿病 动脉粥样硬化 |
Research progress in role of SGLT2i in atherosclerotic cardiovascular disease with diabetes mellitus |
| |
| WANG Ji-Hang,SHEN Ming-Zhi,JIAO Yang and FU Zhen-Hong. Research progress in role of SGLT2i in atherosclerotic cardiovascular disease with diabetes mellitus[J]. Chinese Journal of Multiple Organ Diseases in the Elderly, 2021, 20(4): 300-304 |
| |
| Authors: | WANG Ji-Hang SHEN Ming-Zhi JIAO Yang FU Zhen-Hong |
| |
| Affiliation: | Chinese PLA Medical College, Beijing 100853, China;Department of Cardiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China;Department of Cardiovascular Disease, Hainan Hospital, Chinese PLA General Hospital, Sanya 572013, Hainan Province, China,Department of Cardiovascular Disease, Hainan Hospital, Chinese PLA General Hospital, Sanya 572013, Hainan Province, China,Chinese PLA Medical College, Beijing 100853, China;Department of Cardiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China and Department of Cardiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China;National Center for Clinical Medicine of Geriatric Diseases, Beijing 100853, China |
| |
| Abstract: | Diabetes is a global epidemic, and poor blood glucose control has been one of the primary causes of death for patients with cardiovascular diseases. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a novel hypoglycemic agent, has attracted extensive attention due to their prominent protective action on cardiovascular system in addition to the hypoglycemic effect demonstrated in experimental and clinical studies. Previous large randomized controlled trials for SGLT2i (EMPA-RED, CANVAS, DELCARE TIMI-58) confirmed that SGLT2i, either as primary prevention or as secondary prevention, could significantly reduce the risk of cardiovascular deaths, non-fatal myocardial infarction and non-fatal stroke in patients with coronary artery disease and diabetes mellitus. However, there have been limited findings on the actions of SGLT2i, particularly their direct effects, in atherosclerotic cardiovascular disease (ASCVD). This review summarizes the research progress in the role of SGLT2i in ASCVD with diabetes, in an effort to provide more evidence for the clinical treatment of these patients. |
| |
| Keywords: | cardiovascular diseases SGLT2 inhibitor diabetes mellitus atherosclerosis This work was supported by National Natural Science Foundation of China |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《中华老年多器官疾病杂志》浏览原始摘要信息 |
|
点击此处可从《中华老年多器官疾病杂志》下载全文 |
|
